Charles A. Flentge - Concepedia

Author

Charles A. Flentge

Also Known As

C A Flentge, C Flentge, C. Flentge, C.A. Flentge, Charles A. Flentge, Charles A. Flentge, Charles Flentge, Flentge, Charles A.

Publications

Citations

H-Index

Concepts

All Affiliations

Abbott Fund Abbott (United States)

About

Charles A. Flentge is an author at Abbott Fund specializing in drug discovery, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	360
2	Biochemistry	6	6	327
3	Natural Sciences	4	4	300
4	Immunology	2	2	224
5	Biomolecular Engineering	1	1	39

Charles A. Flentge

Publications

991

Citations

H-Index

Page 1

	Year	Citations
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Dale J. Kempf, Kennan C. Marsh, Jon F. Denissen, Proceedings of the National Academy of Sciences	1995	551
Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy Dale J. Kempf, Hing L. Sham, Kennan C. Marsh, Journal of Medicinal Chemistry ImmunologyPharmacotherapyAntiviral DrugPharmaceutical ChemistryDrug Resistance	1998	204
Highlights of the Structure–Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530) Rolf Wagner, John T. Randolph, Sachin Patel, Journal of Medicinal Chemistry	2018	53
Synthesis and Biological Characterization of B-Ring Amino Analogues of Potent Benzothiadiazine Hepatitis C Virus Polymerase Inhibitors John T. Randolph, Charles A. Flentge, Peggy Huang, Journal of Medicinal Chemistry PharmacotherapyAntiviral DrugPharmaceutical ChemistryHcv PolymeraseMedicinal Chemistry	2009	39
2-Pyridyl P1′-Substituted Symmetry-Based Human Immunodeficiency Virus Protease Inhibitors (A-792611 and A-790742) with Potential for Convenient Dosing and Reduced Side Effects David A. DeGoey, David J. Grampovnik, Charles A. Flentge, Journal of Medicinal Chemistry Comparator CompoundsOral BioavailabilityBioorganic ChemistryConvenient DosingMolecular Biology	2009	30
Oximinoarylsulfonamides as potent HIV protease inhibitors Clinton M. Yeung, Larry L. Klein, Charles A. Flentge, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryMedicineAntiviral Drug DevelopmentPharmacotherapyAntiviral Drug	2005	30
Identification of aryl dihydrouracil derivatives as palm initiation site inhibitors of HCV NS5B polymerase Yaya Liu, Ben Hock Lim, Wen Jiang, Bioorganic & Medicinal Chemistry Letters Hcv Ns5b PolymeraseBiochemistryNatural SciencesAntiviral Drug DevelopmentAryl Dihydrouracil Derivatives	2012	27
955 PRECLINICAL POTENCY, PHARMACOKINETIC AND ADME CHARACTERIZATION OF ABT-333, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR Clarence J. Maring, Renaud Wagner, David Hutchinson, Journal of Hepatology Translational MedicineMedicineImmunologyAntiviral Drug DevelopmentAntiviral Therapy	2009	20
Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs Charles A. Flentge, John T. Randolph, Peggy Huang, Bioorganic & Medicinal Chemistry Letters Cytochrome P450 3APharmacological StudyBiochemistryMedicinePharmacokinetic Enhancement	2009	16
Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors John T. Randolph, Peggy Huang, William J. Flosi, Bioorganic & Medicinal Chemistry Pharmacokinetic EvaluationBiochemistryAntiviral ActivityMedicineAntiviral Drug Development	2006	11

Page 1